Bill Gates’ is about to mint millionaires (again) with Stargate.

This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.

Click here and I’ll tell you everything you need to know.

Jean-Francois Formela net worth and biography

Jean-Francois Formela Biography and Net Worth

Director of Ikena Oncology

Jean-François Formela is a partner and focuses on novel drug discovery approaches and therapeutics. He joined Atlas Venture in 1993 to build the U.S. life sciences franchise.

He is a director and co-founder of IFM Therapeutics, Intellia Therapeutics (NASDAQ: NTLA), Korro Bio, and Triplet Therapeutics. Jean-François also serves on the boards of Ikena Oncology (NASDAQ: IKNA) and Scorpion Therapeutics.

Some of his prior investments include Arteaus Therapeutics (acquired by Eli Lilly), CoStim Pharmaceuticals (acquired by Novartis), Exelixis (NASDAQ: EXEL) and Translate Bio (NASDAQ: TBIO, acquired by Sanofi).

Jean-François received his M.D. from Paris University School of Medicine and his M.B.A. from Columbia University.

How do I contact Jean-Francois Formela?: The corporate mailing address for Dr. Formela and other Ikena Oncology executives is 645 SUMMER STREET SUITE 101, BOSTON MA, 02210. Ikena Oncology can also be reached via phone at 857-273-8343 and via email at [email protected]. Learn More on Jean-Francois Formela's contact information.
Has Jean-Francois Formela been buying or selling shares of Ikena Oncology?: Jean-Francois Formela has not been actively trading shares of Ikena Oncology during the last ninety days. Most recently, Jean Francois Formela sold 8,330 shares of the business's stock in a transaction on Monday, December 13th. The shares were sold at an average price of $14.64, for a transaction totalling $121,951.20. Learn More on Jean-Francois Formela's trading history.
Who are Ikena Oncology's active insiders?: Ikena Oncology's insider roster includes Jean-Francois Formela (Director), and Michelle Zhang (Insider). Learn More on Ikena Oncology's active insiders.

Jean-Francois Formela Insider Trading History at Ikena Oncology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
12/13/2021	Sell	8,330	$14.64	$121,951.20
12/10/2021	Sell	11,989	$15.03	$180,194.67
3/30/2021	Buy	125,000	$16.00	$2,000,000.00

Jean-Francois Formela Buying and Selling Activity at Ikena Oncology

Ikena Oncology Company Overview

Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $1.71

$1.69

$1.73

50 Day Range

MA: $1.71

$1.66

$1.76

2 Week Range

Now: $1.71

$1.22

$2.32

Volume

32,882 shs

Average Volume

60,612 shs

Market Capitalization

$82.52 million

P/E Ratio

N/A

Dividend Yield